IFF to Unveil Breakthrough Alginate Technologies for Biomedical Innovation at WBC and TERMIS

Rhea-AI Summary

IFF (NYSE: IFF), a leader in food, beverage, health, and personal care, will unveil groundbreaking alginate biopolymer technologies at two major biomedical conferences. At the World Biomaterials Congress (WBC) in Daegu, South Korea, from May 26-31, IFF will present a self-gelling alginate hydrogel system that offers a minimally invasive way to deliver therapeutics. This system combines calcium alginate suspension with soluble sodium alginate, which self-gels within minutes of injection.

In June, IFF will present at the TERMIS World Congress in Seattle, showcasing macroporous alginate foam scaffolds for 3D cell culture. These innovations provide non-animal-based cell culture environments, supporting tissue engineering and therapeutic screening. IFF's NovaMatrix® portfolio of ultrapure alginate biopolymers is poised to revolutionize regenerative medicine and 3D cell culture applications.

Positive

• IFF will present a groundbreaking self-gelling alginate hydrogel system at WBC, which offers a minimally invasive way to deliver therapeutics.
• IFF will showcase macroporous alginate foam scaffolds for 3D cell culture at TERMIS, enhancing tissue engineering and therapeutic screening.
• IFF's NovaMatrix® portfolio of ultrapure alginate biopolymers could revolutionize regenerative medicine and 3D cell culture applications.
• The self-gelling hydrogel system combines calcium alginate suspension with soluble sodium alginate, self-gelling within minutes of injection.
• IFF provides non-animal-based cell culture environments, which is important for ethical biomedical research.

Negative

• The PR lacks specific financial data, such as revenue projections or cost implications of the new technologies.
• No information is provided on the commercial readiness or regulatory approval status of the new alginate technologies.

NEW YORK, May 27, 2024 /PRNewswire/ -- IFF (NYSE:  IFF), a global leader in food and beverage, home and personal care and health will unveil groundbreaking study results at upcoming major biomedical conferences. These results highlight how IFF Pharma Solutions NovaMatrix^® portfolio of ultrapure alginate biopolymers could revolutionize regenerative medicine and 3D cell culture applications. At the 12^th World Biomaterials Congress (WBC), IFF Pharma Solutions will showcase a first-of-its-kind alginate hydrogel system that self-gels, offering a minimally invasive way to deliver therapeutics. The company will then reveal how its unique porous alginate foam scaffolds can be utilized for 3D cell culture at the TERMIS World Congress.

Breakthrough alginate hydrogel system in the spotlight at WBC

At WBC in Daegu, South Korea, May 26-31, booth #74, visitors will learn how IFF is breaking boundaries in the biotech space with novel alginate biopolymer technologies. During a poster session on May 28 at 06:00 PM (Korean standard time), Caroline Cooreman, global business development & product manager, Biotechnology, IFF Pharma Solutions, will reveal groundbreaking alginate hydrogel system that self-gels within minutes after injection. This is enabled by combining a calcium alginate suspension with soluble sodium alginate. The resulting self-gelling hydrogel system could transform regenerative medicine by providing a minimally invasive alternative to surgical implantation procedures for delivering therapeutic cells, proteins, or drugs.

"Our revolutionary self-gelling technology is just one aspect of our alginate innovation that we're illuminating at WBC," said Caroline Cooreman. "Through our unmatched polymer expertise and rigorous research, we understand how to tailor the viscosity and strength of our alginate gels by selecting specific alginate monomer compositions and molecular weights. This allows us to create custom gels optimized for our customers' unique formulation needs."

Pioneering alginate foam scaffolds to be featured at TERMIS

IFF will continue its alginate innovation showcase just weeks later at the 7^th TERMIS World Congress in Seattle, Washington, June 25-28. Mark Dreibelbis, senior scientist, IFF Pharma Solutions, will reveal pioneering macro-porous alginate foam scaffolds for 3D cell culture on Wednesday June 26, at 7:05 PM PDT in Hall 4A with a follow-up on Thursday, June 27, at 6:15 PM PDT in Hall 4A. The presentation titled, Macroporous Alginate Foam Scaffolds for 3D Cell Growth will be part of the theater and poster sessions at the conference.

Leveraging its deep expertise in alginates and customization capabilities, IFF has tuned the foam scaffolds to achieve 3D culture conditions for various cell types based on customer needs. By offering practical methods for cell seeding and release, the alginate foams offer a non-animal-based cell culture environment which could support tissue engineering and therapeutic screening applications.

"As the only supplier of ultrapure and sterile alginates, we're excited about how our industry leading NovaMatrix^® portfolio is propelling the biotech field forward," added Caroline. "The latest research we're revealing at WBC and TERMIS will provide our customers with transformative solutions for next-generation biotherapeutics – from controlled hydrogel technologies to advanced 3D cell culture platforms. Looking ahead, we will continue to actively research and advance the impact that our high-quality alginate polymers can bring to further support our customers in the biomedical industry."

For more information about IFF's industry-leading portfolio of ultrapure NovaMatrix^® biopolymers, visit IFF Pharma Solutions and stop by at either of IFF's upcoming events or tune in to our June 5 webinar, "Advancing cell therapy: innovations in polymer-based encapsulation and delivery". Register here. 

 Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, X (Twitter) , Facebook, Instagram, and LinkedIn.

©2024 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ^TM, ^SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Contact:
Reena Chaudhary
Global Communications Manager
+91 9769820494
reena.chaudhary@iff.com

SOURCE IFF

FAQ

What new technology is IFF unveiling at the WBC?

IFF will unveil a self-gelling alginate hydrogel system at the WBC, which offers a minimally invasive way to deliver therapeutics.

When and where will IFF present their new technology?

IFF will present at the World Biomaterials Congress (WBC) in Daegu, South Korea, from May 26-31, and at the TERMIS World Congress in Seattle, from June 25-28.

What is the significance of IFF's NovaMatrix® portfolio?

IFF's NovaMatrix® portfolio includes ultrapure alginate biopolymers that could revolutionize regenerative medicine and 3D cell culture applications.

What are the applications of IFF's new alginate technologies?

IFF's new alginate technologies can be used for minimally invasive therapeutic delivery and non-animal-based 3D cell culture, supporting tissue engineering and therapeutic screening.

How does IFF's self-gelling hydrogel system work?

IFF's self-gelling hydrogel system combines a calcium alginate suspension with soluble sodium alginate, which self-gels within minutes after injection.